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Summary
The endocannabinoid system plays a role in regulating bone
mass and bone cell activity and inactivation of the type 1 (Cnr1)
or type 2 (Cnr2) cannabinoid receptors influences peak bone
mass and age-related bone loss. As the Cnr1 and Cnr2 receptors
have limited homology and are activated by different ligands,
we have evaluated the effects of combined deficiency of Cnr1
and 2 receptors (Cnr1/2/) on bone development from birth to
old age and studied ovariectomy induced bone loss in female
mice. The Cnr1/2/ mice had accelerated bone accrual at birth
when compared with wild type littermates, and by 3 months of
age, they had higher trabecular bone mass. They were also
significantly protected against ovariectomy-induced bone loss
due to a reduction in osteoclast number. The Cnr1/2/ mice had
reduced age-related bone loss when compared with wild-type
due to a reduction in osteoclast number. Although bone
formation was reduced and bone marrow adiposity increased
in Cnr1/2/ mice, the osteoclast defect outweighed the
reduction in bone formation causing preservation of bone mass
with aging. This contrasts with the situation previously reported
in mice with inactivation of the Cnr1 or Cnr2 receptors
individually where aged-related bone loss was greater than in
wild-type. We conclude that the Cnr1 and Cnr2 receptors have
overlapping but nonredundant roles in regulating osteoclast
and osteoblast activities. These observations indicate that
combined inhibition of Cnr1 and Cnr2 receptors may be
beneficial in preventing age-related bone loss, whereas block-
ade of individual receptors may be detrimental.
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Introduction
Endogenous cannabinoid (endocannabinoid) ligands and their receptors
play important roles in the regulation of bone mineral density in animal
models of bone disease (Bab et al., 2009; Idris & Ralston, 2012) and in
human (Sophocleous et al., 2017). The endocannabinoid system
comprises two known receptors, a family of endogenous ligands and
various enzymes that are responsible for ligand synthesis, transport and
inactivation. Endocannabinoid ligands and their receptors regulate a
wide variety of neurological functions including appetite control, pain
perception, motor function and the immune response (Matsuda et al.,
1990; Idris & Ralston, 2010). There are two classic cannabinoid
receptors: type 1 (Cnr1) and type 2 (Cnr2) receptors, both of which
belong to the G protein-coupled receptor (GPCR) super-family (Pertwee
& Ross, 2002; Demuth & Molleman, 2006). The Cnr1 receptor is
strongly expressed in the nervous system (Matsuda et al., 1990; Idris &
Ralston, 2010), whereas Cnr2 is predominately expressed in cells of the
immune system (Munro et al., 1993). However, both receptors are also
expressed in bone cells including osteoclasts, osteoblasts, osteocytes
and chondrocytes (Tam et al., 2006, 2008; Idris et al., 2009; Idris &
Ralston, 2010; Ofek et al., 2011). The endocannabinoids anandamide
(AEA) and 2-arachidonoylglycerol (2-AG) and a variety of plant
cannabinoids act as an agonist at both Cnr1 and Cnr2 receptors albeit
with different degrees of selectivity (Matias et al., 2002; Mechoulam,
2005). The endocannabinoids AEA and 2-AG are produced within the
central nervous system and in the bone microenvironment by
osteoblasts and osteoclasts (Tam et al., 2006, 2008; Rossi et al.,
2009; Idris & Ralston, 2010; Whyte et al., 2011). Agonists of Cnr1 and
2 receptors inhibit adenylyl cyclase causing reduction in intracellular
levels of cyclic adenosine monophosphate and activation of a variety of
downstream signalling pathways including ion channels, Nuclear Factor
Kappa-B (NFjB), phosphoinositide kinase, mitogen-activated protein
kinase and modulation of second messengers such as ceramide and
intracellular calcium (Demuth & Molleman, 2006; Idris & Ralston,
2010).
Studies in genetically modified mice implicated both Cnr1 and Cnr2 in
the regulation of peak bone mass and age-related bone loss. We have
reported that adult Cnr1 knockout female mice on inbred (ABH) and
outbred (CD1) backgrounds have high peak bone mass and are
protected against ovariectomy-induced bone loss due to an osteoclast
defect (Idris et al., 2005). However, the same animals develop low bone
mass with increasing age due to a defect in bone formation (Idris et al.,
2009). In contrast to these findings, Tam and colleagues reported that
female mice with Cnr1 deficiency exhibit low peak bone mass when
inbred onto a C57BL/6 background (Tam et al., 2006). However, we and
others have reported that female Cnr2 knockout mice develop low bone
mass with age due to a decrease in bone formation (Ofek et al., 2006;
Sophocleous et al., 2014a,b). Together, these findings demonstrate that
both Cnr1 and Cnr2 receptors play a role in bone metabolism but
suggest that their effects are to some extent distinct. Studies in humans
have shown that heavy use of recreational cannabis, which is known to
activate both Cnr1 and 2 receptors, is associated with low bone mineral
density and increased bone turnover (Sophocleous et al., 2017). As the
individual cannabinoid receptors play a role in skeletal homeostasis, we
generated mice with combined deficiency in Cnr1 and Cnr2 on the
outbred CD1 genetic background and evaluated the consequences of
combined deficiency of both Cnr1 and 2 receptors on bone metabolism
in mice.
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Results
Deficiency of Cnr1/2 has no effect on survival or body weight
External examination of neonates and adult (day 1–360) Cnr1/2/ mice
showed no discernible phenotype. The mice exhibited no signs of
impaired reproduction and survived normally when compared to wild-
type littermates in the breeding colony. These general observations are
similar to those previously reported in mice deficient in the Cnr1 or Cnr2
receptors (Idris et al., 2005, 2009; Ofek et al., 2006; Sophocleous et al.,
2014a,b). Body weight is an important determinant of bone mass, and
previous studies have shown that both Cnr1 and Cnr2 receptors play a
role in the regulation of appetite and body weight (Colombo et al.,
1998; Kirkham &Williams, 2001; Cota, 2007; Agudo et al., 2010). Here,
we report that body weight was comparable between Cnr1/2/ and
wild-type (wt) control mice at birth, 7, 90, 180 and 360 days and after
oestrogen cessation in ovariectomized 3-month-old mice (Fig. 1c and
Table S1).
Deficiency of Cnr1/2 enhances embryonic bone accrual
Skeletal phenotyping of mice at birth revealed that Cnr1/2/ female
mice had accelerated embryonic bone accrual and exhibited 100%
increase in bone volume when compared to wild-type control mice of
similar age (Fig. 1a–b). This suggests combined deficiency of Cnr1 and 2
enhances bone accrual during embryonic development.
Deficiency of Cnr1/2 increases bone mass during adulthood
We next investigated the effects of combined deficiency of Cnr1 and 2
on bone mass in 3-month-old mice. As shown in Fig. 1 (panels d – f),
Cnr1/2/ female mice at this age exhibited a significant increase in
trabecular bone volume (Fig. 1d,f) and number (Fig. S2a), coupled with
significant reduction in trabecular separation (Fig. 1e) at the tibial and
femoral metaphysis and spine. Analysis of cortical bone parameters
revealed that Cnr1/2/ female mice had increased cortical area (Fig. 1g,
i) and thickness (Fig. 1h) at the femoral diaphysis and were more
resistant to fracture (Fig. 3b). No significant differences between wild-
type and Cnr1/2/ female mice were detected at the tibial diaphysis at
this age. A similar increase in trabecular bone mass (Fig. S2a–b), but not
in cortical (Fig. S2c–d), bone mass at the femoral metaphysis was also
observed in male Cnr1/2/ mice of similar age when compared to male
wild-type controls.
Deficiency of Cnr1/2 attenuates age-related trabecular bone
loss
We went on to examine whether combined deficiency in Cnr1 and Cnr2
affects the development of age-related bone loss in aged female mice.
We observed that both wild-type and Cnr1/2/ female mice had lower
trabecular bone mass by the age of 12 months as compared with
3 months of age, but trabecular bone mass in Cnr1/2/ mice at
12 months was better preserved than in wild-type mice. The values for
trabecular bone volume (mean  SD) were 41.7  11.7 (n = 8) and
40.6  14.6% (n = 8), lower at the tibial metaphysis and femoral
metaphysis, respectively, in Cnr1/2/ mice compared with 50  4.7%
(n = 8, P < 0.05) and 82  9.7% (n = 8, P < 0.01) lower in wild-type
controls. MicroCT analysis of the trabecular bone compartment revealed
that Cnr1/2/ mice at this age had significantly high trabecular bone
volume and number, and lower trabecular separation at tibial
metaphysis, femoral metaphysis and spine (Figs 2a,b and S4a,b).
Analysis of cortical bone parameters (Fig. 2d–e) revealed that Cnr1/2/
 exhibited high cortical area and thickness and reduced marrow
diameter (Fig. S4d) in the femoral diaphysis, whereas no significant
differences between wild-type and Cnr1/2/ female mice were
detected at the tibial diaphysis (Fig. S4c–d). Representative microCT
images of trabecular and cortical bone in Cnr1/2/ female mice and
wild-type control visualized at this age are shown in Fig. 2, panels c and
f. These data indicate that combined deficiency in Cnr1 and 2 protects
against age-related trabecular bone loss in aged female mice.
Deficiency of Cnr1/2 enhances bone strength in aged mice
To assess the effect of combined deficiency of Cnr1 and 2 on bone
strength, three-point bending tests were performed in mice of 3 and
12 months of age. As shown in Fig. 3, combined Cnr1 and 2
deficiency was associated with increased tibial and femoral bone
strength in 12-month-old female mice, with a significant increase
(P < 0.05) in load to failure (+16% in tibia and +35% in femur)
(Fig. 3a); fracture (+29% in tibia and +68% in femur) (Fig. 3b);
maximum stiffness (+36% in tibia and +26% in femur) (Fig. 3c); and
yield (+24% in tibia and +31% in femur) (Fig. 3d) compared with age-
matched wild-type controls. Pearson’s correlation analysis revealed
significant correlations between cortical area and biomechanical
variables including stiffness (data not shown), and the peak load for
fracture and failure at the femoral diaphysis for the Cnr1- and Cnr2-
deficient group at 12 months of age (P < 0.05) (Fig. 3e,f). At the tibial
diaphysis, only the relationship between cortical area and fracture peak
load was significant in Cnr1- and Cnr2-deficient mice (data not
shown). The regression lines for the wild-type group at 12 months of
age showed no significant correlation between cortical area and bone
strength.
Effects of oestrogen deficiency and replacement on bone
mass in Cnr1/2-deficient mice
To determine whether combined deficiency of Cnr1 and Cnr2 modulates
the skeletal response to oestrogen, we studied the effects of ovariec-
tomy on bone loss in Cnr1/2/ and wild-type female mice at 3 months
of age (Fig. 4a). This showed that Cnr1/2/ mice were partially
protected against ovariectomy-induced bone loss as compared with
wild-type (Fig. 4b–e). Furthermore, the decrease in trabecular bone
volume (Fig. 4b) was greater in wild-type control than in ovariectomized
Cnr1/2/ mice (P < 0.05). We also went on to study the effects of
oestrogen in older Cnr1/2/ female mice (Fig. 4f). At 9 months of age,
Cnr1/2/ and wild-type female mice received either placebo or 17b-
estradiol (E2, 40 lg kg1) pellets. By 12 month of age, E2 significantly
increased trabecular bone volume, trabecular number and reduced
trabecular separation in both Cnr1/2/ and wild-type control mice
(Fig. 4, panels g–j). The increase in trabecular bone volume was greater
in Cnr1/2/ mice than in wild-type mice (P < 0.05).
Bone metabolism in mice with combined deficiency of Cnr1/2
as compared with mice with deficiency of a single receptor
Analysis of the bone parameters reported in this study and those which
we previously reported in mice of the same genetic background are
shown in Table 2. Mice deficient in Cnr1, Cnr2 or both Cnr1/2 exhibited
higher peak bone mass at 3 month of age as compared with wild-type
due to a significant reduction in osteoclast number (Tables 1 and 2).
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With aging, Cnr1/2/ continued to have higher bone mass than wild-
type despite a reduction in osteoblast number. This contrasts with the
situation in Cnr2/ mice and Cnr1/ mice where bone mass was lower
in aged mice compared with wild-type due to an osteoblast defect
(Tables 1 and 2). These findings indicate that genetic inactivation of both
Cnr1 and Cnr2 receptors affects peak bone mass in a similar way to
inactivation of the single receptors. However, with aging, the osteoclast
defect in Cnr1/2/ mice outweighs the effect of the osteoblast defect
causing relative preservation of bone mass.
Osteoclast numbers and bone resorption are reduced in Cnr1/
2-deficient mice
To define the mechanisms responsible for the increased trabecular bone
mass associated with Cnr1/2 deficiency, we studied bone histomor-
phometry in Cnr1/2/ and wild-type female mice. This showed that
active resorption surface and osteoclast numbers were significantly
lower in Cnr1/2/ when compared with wild-type at both 3 months
and 12 months (Table 1). In keeping with this, quantitative PCR analysis
of various osteoclast-specific genes in mature osteoclast cultures and in
calvarial osteoblasts revealed that mRNA levels of acp5 (TRAcP),
tnfrsf11a (RANK), Tcirg1 and Itgb3 in osteoclasts (Fig. 5a) and tnfs11
(RANKL) and tnfrsf11b (OPG) in calvarial osteoblasts (Fig. 5a, right panel)
were significantly lower in Cnr1/2/ cultures than in wild-type control
cultures. In contrast, the mRNA expression of Itgb3 and Cathepsin K
(CTSK) was not affected in Cnr1/2/ cultures when compared to
cultures from wild-type controls.
Bone formation is reduced in aged female mice with Cnr1/2
deficiency
Analysis of bone formation parameters revealed no changes in bone
formation and mineral apposition rate at the age of 3 month but mild
reduction in osteoblast number was detected in Cnr1/2/ mice
Fig. 1 Accelerated bone accrual in
neonates and increased trabecular bone
mass in adult female mice with combined
deficiency in Cnr1 and Cnr2 receptors. (a)
Total bone volume (BV, mm3) of wild-type
(wt, n = 7) and Cnr1/2/ (n = 8) mice at
birth as assessed by microCT analysis. (b)
Representative microCT images of lateral
and posterior view from mice described in
panel a. (c) Total body weight (gram) of
wild-type (wt, n = 7) and Cnr1/2/ (n = 8)
mice from the experiment described in a
and b. (d–i) Trabecular and cortical bone
parameters in Cnr1/2 double-knockout
(Cnr1/2/) CD1 mice (n = 7) and wild-type
(wt, n = 7) control assessed at 3 months of
age at the tibial, femur and vertebrae L6 by
microCT (d: trabecular volume, BV/TV (%);
e, trabecular separation, Tb.Sp. (lm); g,
cortical area, Ct.Ar (lm2) h; cortical
thickness, Ct. Th. (lm). (f and i)
Representative microCT images of
trabecular (f) and cortical (i) bone from
tibiae and femurs of the mice described in
panels d, e, g, h. Values are mean  SEM.
*P < 0.05, Cnr1/2/ versus wild-type
groups.
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(Table 1). By 12 months of age, Cnr1/2/ mice suffered a significant
reduction in osteoblast number and mineralizing surface (Table 1), but
bone mineral apposition rate remained unchanged (Table 1). We also
detected a significant reduction in the mRNA expression of the
osteoblast-specific genes Runt Related Transcription Factor 2 (rnx2),
alkaline phosphatase (alpl), osteopontin (opn) and cadherin-11 (cdh11)
in bone marrow-generated osteoblasts obtained from aging Cnr1/2/
mice at 12 months of age (Fig. 5b–d).
Blockade of Cnr1, but not Cnr2, enhances adipocyte
differentiation
Histological analysis of the bone marrow compartment revealed
increased numbers and accumulation of adipocytes in both Cnr1/2/
and Cnr1/ mice, but this was more evident in Cnr1/ mice where the
trabecular marrow space was almost completely replaced with adipocytes
(Fig. 6a,b). The difference in adipocyte number that was observed in
Cnr1/2/ knockout was not significantly different to those observed in
single knockouts of Cnr1 (Fig. 6a). In contrast, the space occupied by
adipocytes in the bone marrow compartment of female Cnr2/ mice at
this age was significantly lower than in Cnr1/ and Cnr1/2/ mice
(Fig. 6a). Mice with deficiency of the Cnr1 receptor exhibited a significant
reduction in bone marrow fat accumulation compared to wild-type
controls (Fig. 6b), confirming the role of Cnr1 in this process. Taken
together these observations suggest that Cnr1 plays a more important
role than Cnr2 in regulating bone marrow adipocyte differentiation. To
further investigate the contribution of Cnr1 to adipocyte differentiation,
we studied the expression of Cnr1 and a number of adipocyte-specific
genes in cultures of the preadipocyte 3T3-L1 cells in the presence and
absence of adipogenic medium and the Cnr1-selective inverse agonist
AM251. We observed a significant increase in the protein level of Cnr1 in
the cultures of the preadipocyte 3T3-L1 exposed to adipogenic medium
(Fig. 6c,d) and showed that under these conditions, the Cnr1-selective
inverse agonist AM251 increased adipocyte number (Fig. 6e–f),
enhanced the protein expression of the adipocyte-specific FABP4 (Fig. 6i)
and significantly increased the mRNA expression of CCAAT/enhancer
binding protein alpha (CEBPa), lipoprotein lipase (LPL), adrenoceptor beta
3 (Adrb3), peroxisome proliferator-activated receptor gamma (PPARc),
Adipsin (CFD, complement factor D) and beta-glucosidase 4 (GLU4), all of
which are key regulators of adipocyte differentiation and maturation
(Champigny et al., 1992; Ntambi & Young-Cheul, 2000; Burton et al.,
2004). It is important to note that AM251 had no significant effects on
the proliferation of 3T3-L1 under these conditions excluding the
possibility that the stimulatory effect on adipogenesis was mediated by
an increase in cell number (Fig. 6g–h).
Discussion
Over recent years, there has been increasing interest in the role that
endocannabinoids and their receptors play in the regulation of bone
metabolism (Bab et al., 2009; Idris & Ralston, 2012). Genetic inactivation
of Cnr1on an outbred (CD1) background is associated with increased
peak bone mass due to reduced osteoclast number but is associated with
lower bone mass with age due to reduced bone formation and
accumulation of adipocytes in the bone marrow. Mice deficient in
Cnr2 on the same background also have higher peak bone mass than
wild-type but developed lower bone mass on aging, due to reduced
bone formation. Unlike Cnr1/ mice, elderly Cnr2/ mice do not
accumulate fat in the bone marrow. The observations presented here
show that combined deficiency in Cnr1 and Cnr2 enhances bone accrual
Fig. 2 Aged female mice with combined
deficiency in Cnr1 and Cnr2 receptors
exhibit high bone mass. Trabecular and
cortical bone parameters in Cnr1/2 double-
knockout (Cnr1/2/) CD1 mice (n = 9)
and wild-type (wt, n = 7) control assessed
at 12 months of age at the tibia, femur and
vertebrae L6 by microCT (a: trabecular
volume, BV/TV (%); b, trabecular
separation, Tb.Sp. (lm); d, cortical area,
Ct.Ar. (lm2) e; cortical thickness, Ct. Th.
(lm). (c and f) Representative microCT
images of trabecular (c) and cortical bone
(f) from tibiae and femur of the mice in
panels a, b, d, e. Values are mean  SEM.
Significant differences between WT and
Cnr1/2/ groups are indicated by
*P < 0.05, **P < 0.01 and ***P < 0.001.
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and increases peak bone mass in adult mice due to an effect on
osteoclast number and function. In addition, we detected a small
reduction in osteoblast number in Cnr1/2/ mice, but bone formation
parameters including bone formation rate and mineral apposition rate
remained unchanged. The differences in peak trabecular bone mass and
osteoclast and osteoblast numbers were quantitatively similar to those
previously observed in single knockout of Cnr1 and 2 of a similar age on
the same genetic background (Idris et al., 2009; Sophocleous et al.,
2014a,b). Collectively, our results suggest that enhanced bone accrual
during skeletal growth and increased levels of trabecular bone mass
associated with single or double Cnr1 and 2 deficiencies was most
probably driven by a reduction in osteoclast number.
Oestrogen positively regulates peak bone mass, and oestrogen
deficiency is associated with increased bone loss (Richelson et al.,
Fig. 3 Increased bone strength in aged
female mice with combined deficiency in
Cnr1 and Cnr2 receptors. Bone strength
parameters in Cnr1/2 double-knockout
(Cnr1/2/) CD1 mice and wild-type (wt)
control assessed at 3 and 12 months of age
at the tibial and femoral diaphysis by three-
point bending (a, Failure, Newton; b,
Fracture, Newton; c, Maximum stiffness,
Newton; d, Yield, Newton). Values are
mean  SEM from at least six mice per
group. Significant differences between WT
and Cnr1/2/ groups are indicated by
**P < 0.05. Pearson’s correlation analyses
were performed across 12-month-old wild-
type and Cnr1- and Cn2-deficient mice
groups between cortical area (Ct.Ar) and
peak failure (e) and (f) facture loads at the
femoral diaphysis. Pearson correlation
coefficients (R) are indicated on each graph.
*P < 0.05 indicates significant correlation
between variables.
Osteoprotection by Cnr1/2 deficiency, A. Sophocleous et al. 1055
ª 2017 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd.
1984; Pacifici, 1996; Raisz, 1996). Previous studies have shown that
single deficiency in Cnr1 or Cnr2 in mice is associated with reduced
bone density with age and that pharmacological blockade of these
receptors causes osteoclast inhibition and prevents bone loss in
ovariectomized adult mice (Idris et al., 2005, 2009; Sophocleous et al.,
2011). Here, we observed that Cnr1/2 double-knockout mice were
also protected against ovariectomy-induced bone loss in adult mice,
with results identical to those observed with the single Cnr1 or Cnr2
knockout mice and after administration of pharmacological blockers of
these receptors (Idris et al., 2005, 2008, 2009). In addition, Cnr1/2
double-knockout mice at 12 month of age were relatively protected
against age-related bone loss compared with wild-type. This was
associated with an increase in energy to fracture and failure,
suggesting the increased cortical bone mass was preserving bone
strength. These data suggest that combined deficiency in Cnr1 and 2
has a positive effect on bone density and strength in aged female
mice, which is in contrast with previous studies that have shown that
single deficiency of Cnr1 or Cnr2 in female mice is associated with
increased aged-related bone loss (Ofek et al., 2006; Idris et al., 2009;
Sophocleous et al., 2014a). It is important to note that female mice
with combined deficiency in Cnr1 and Cnr2 used in this study – unlike
Cnr1-deficient mice of similar age (Idris et al., 2005, 2009) – showed
no significant difference in body weight throughout life when
compared to wild-type control. These findings indicate that combined
deficiency in Cnr1 and 2 enhances bone mass by an effect that is
independent of body weight.
Fig. 4 Effects of oestrogen deficiency and replacement on bone mass in Cnr1/2 double-knockout aged female mice. (a–e) Trabecular bone volume (b, BV/TV, %), number
(c, Tb. N., lm1) and separation (d, Tb.Sp., lm) and trabecular pattern factors (e, Tb.Pf, lm1) in sham and ovariectomized 3 month Cnr1/2 double-knockout
(Cnr1/2/, n = 7) CD1 mice and wild-type control (n = 6) assessed at the tibial metaphysis by microCT. (f–j) Trabecular bone parameters in 12-month-old Cnr1/2 double-
knockout (Cnr1/2/) CD1 mice and wild-type control treated with placebo (n = 7) or estradiol (E2, 40 lg kg1 day1, n = 7) for 3 months and bone parameters assessed
at the tibial metaphysis by microCT (a: bone volume, BV/TV (%); b: trabecular number, Tb. N. (lm1); c: trabecular separation, Tb.Sp. (lm); d, trabecular pattern factor,
Tb.Pf. (lm1). Values are mean  SD. *P < 0.05, wild-type versus Cnr1/2/ groups, $P < 0.05, wild-type sham and ovariectomized (ovx) groups and +P < 0.05, placebo
and E2 groups.
Table 1 Static and dynamic histomorphometry in Cnr1/2 double-knockout (Cnr1/2/) and wild-type mice
Age Genotype
Oc.N/BS
(cells mm1) Act.Res/BS (%)
Ob.N/BS
(cells mm1)
MAR
(lm day1) MS/BS (%) BFR/BS (l)m3 (l)m2 day1 AdipoS/BS (%)
3 months Wild-type 0.78  0.18 2.45  0.19 22.5  1.6 4.1  0.2 51.9  1.5 2.1  0.2 0.013  0.01
CNR1/2/ 0.60  0.16* 1.9  0.12* 17.9  1.0 4.3  0.1 51.6  0.8 2.2  0.1 0.011  0.01
12 months Wild-type 1.7  0.2 4.9  0.5 17.6  1.5 1.7  0.4 46.8  1.7 0.8  0.05 0.09  0.01
CNR1/2 / 1.4  0.1* 4.5  0.4** 11.7  0.1** 1.8  0.1 32.8  2.6** 0.6  0.06** 0.30  0.07**
Act.Res; active resorption surface/bone surface (%); Oc.N/BS, osteoclast number/bone surface (cells/mm); AdipoS/BS, adipocyte surface/bone surface (%); Ob.N/BS,
osteoblast number /bone surface (cells/mm); MAR, mineral apposition rate (lm day1); MS/BS, mineralizing surface/bone surface (%); BFR/BS: bone formation rate/bone
surface (l)m3 (l)m2 day1; values are means  SEM and are obtained from six to eight animals. *P < 0.05, **P < 0.01 between genotype groups.
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Histomorphometric analysis in aged Cnr1/2 double-knockout mice
showed a reduction in osteoclast and osteoblast numbers, a reduction in
bone formation rate and an increase in bone marrow fat accumulation.
The reduction in bone formation is consistent with previous studies in
single Cnr1 and 2 mice (Table 2 and (Ofek et al., 2006; Tam et al.,
2008; Ofek et al., 2011; Sophocleous et al., 2011) and with previous
work that showed that cannabinoid receptor activation in osteoblasts
exerts an anabolic effect (Ofek et al., 2006, 2011; Sophocleous et al.,
2011). We speculate that the likely mechanism for the higher bone mass
in aged Cnr1/2 double-knockout mice compared with single cannabi-
noid receptor deficiency is a relative reduction in osteoclast number
which outweighs the reduction in osteoblast activity and increased
adipocyte differentiation that was also observed.
Previous studies using Cnr1 knockout mice have shown an increase in
adipocyte accumulation in the bone marrow that was found to be
associated with a decrease in osteoblast differentiation and function
(Idris et al., 2009). In contrast, our present data and those reported by
our group in previous studies have demonstrated that aged Cnr2-
deficient mice in both CD1 and C57BL/6 backgrounds have fewer
adipocytes in the bone marrow compartments than wild-type littermates
(Sophocleous et al., 2014a). Here, we found that aged Cnr1/2-deficient
mice had a similar degree of adipocyte accumulation to mice with single
deficiency of Cnr1 (Idris et al., 2009). This demonstrates that the Cnr1
plays a more important role than Cnr2 in regulating adipocyte
differentiation in bone marrow. In keeping with this, we observed that
Cnr1 expression was significantly enhanced following exposure of the
preadipocyte 3T3-L1 cells to adipogenic medium in vitro and activation
of Cnr1 by the selective inverse agonist AM251 (Champigny et al., 1992;
Ntambi & Young-Cheul, 2000; Burton et al., 2004).
In conclusion, our present data together with previous results
obtained with single Cnr1 or Cnr2 (Table 2) knockout mice and after
administration of the Cnr1 AM251 (Idris et al., 2005, 2009) and Cnr2
Fig. 5 Combined deficiency in Cnr1 and 2
receptors reduces the expression of
osteoclast and osteoblast-specific genes. (a
– b) The expression of osteoclast (a)- and
osteoblast (b)-specific genes was measured
by RT–PCR followed by qPCR. Transcript
numbers are expressed as copy number per
mg and normalized over of 18s RNA.
Values in the graphs are mean  SD and
are obtained from three independent
experiments (*P < 0.05, **P < 0.01, from
wild-type). RANKL- and M-CSF-generated
osteoclast, bone marrow osteoblast and
calvarial osteoblast cultures were obtained
from three independent experiments.
Abbreviations and primers are listed in
Table S2. (c – d) Representative
photomicrographs of trabecular bone from
the tibial metaphysis of Cnr1/2 double-
knockout (Cnr1/2/) and wild-type control
female mice at 12 months of age showing
(c) osteoclasts (tartrate-resistant acid
phosphatase [TRAcP] staining, black
arrows) and (d) bone surface (double
Calcein labelling, red arrows).
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Fig. 6 Blockade of Cnr1, but not Cnr2, enhances adipocyte differentiation in vitro and in vivo. (a) Quantification of adipocyte numbers at the tibial metaphysis in mice with
Cnr1, 2 or both receptor deficiencies at 12 months of age. NS, not significantly different from Cnr2; *P < 0.05 from wild-type; +P < 0.05 from Cnr2. (b) Representative
photomicrographs of bone from panel a showing bone (Von Kossa staining, black) and bone marrow adipocyte (dotted line). (c – d) Western blot analysis of the Cnr1
receptor in the preadipocyte 3T3-L1 cells cultured in standard or adipogenic medium for the indicated period. $P < 0.05 from standard medium treated cultures (e – h)
Quantification of adipocyte numbers by staining with Nile Red (e) and viability by AlamarBlue assay (g) in cultures of the preadipocyte 3T3-L1 cells treated with vehicle (0.1%
DMSO) or the CB1-selective inverse agonist AM251 in the presence of insulin (1 lg mL1) for 10 days. (f and h) Representative photomicrographs of adipocytes in the
presence (f) or absence (h) of Nile Red staining (X10 magnification). (i) The protein level of FABP4 in the 3T3-L1 cells described in panels e – h as assessed by Western blot
analysis, (i) The mRNA expression of the adipocyte-specific genes CCAAT/enhancer binding protein alpha (CEBPa); lipoprotein lipase (LPL); adrenoceptor beta 3 (Adrb3);
peroxisome proliferator-activated receptor gamma (PPARc); Adipsin (complement factor D, CFD) or beta-glucosidase 4 (GLU4) in the 3T3-L1 cells described in panels e – i as
assessed by RT–PCR followed by qPCR, (j) in the 3T3-L1 cells described in panels e – h as assessed by Western blot analysis and qPCR, respectively. *P < 0.05 and
***P < 0.001 from vehicle treated. Transcript numbers are expressed as copy number per mg of 18s RNA. Data are from three independent experiments (n = 3).
Abbreviations and primers are listed in Table S2.
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AM630 (Idris et al., 2008)-selective blockers suggest that Cnr1 and 2
have distinct roles in skeletal homeostasis and their combined inhibition
protects against age-related bone loss primarily by inhibiting bone
resorption. These findings indicate that combined inhibition of both
Cnr1 and Cnr2 receptors could be of value in the prevention of
age-related bone loss due to their inhibitory effects on osteoclast
number, although it remains to be seen whether this strategy would
have clinical utility given the many other osteoclast inhibitors that are
currently available for clinical use.
Experimental procedures
Animal experiments
Animals were housed under standard conditions of temperature
(25  1°C) and relative humidity (60  10%) on 12-hour light/dark
cycle with ad libitum access to standard pellet diet and tap water.
Generation of Cnr1 and Cnr2 double-knockout mice on a CD1
genetic background
Mice with targeted inactivation of Cnr1 on the inbred C57BL/6
background were generated by homologous recombination as described
previously (Ledent et al., 1999; Marsicano et al., 2002) and were a kind
gift from Dr Christine Ravinet-Trillou (Sanofi-Aventis). Mice with Cnr2
deficiency were obtained from Dr Susana Winfield at the NIH and were
generated as previously described (Sophocleous et al., 2011). These mice
had previously been crossed with wild-type C57BL/6 mice for at least 10
generations to create a congenic strain on a C57BL/6 background.
Heterozygous mice from Cnr1 or Cnr2 on the C57BL/6 were bred for at
least 17 generations onto a CD1 background before generating the
wild-type and Cnr1/2/ from different litters. The Cnr1 and 2 mice used
in this study were generated by mating of heterozygote breeding pairs.
A congenic strain of mice with combined inactivation of both receptors
was generated by crossing a homozygote Cnr1 male and homozygote
Cnr2 female on the CD1 background (Fig. S1a). Combined inactivation
of Cnr1 and 2 genes in homozygous Cnr1/2/ mice was confirmed by
absence of Cnr1 and 2 cDNA (Fig. S1b). Body weight was monitored at
the same time at day 1 and 7 and after 3, 6 and 12 months of age.
Ovariectomy and hormone replacement
All animal experiments were approved by the Animal Welfare and Ethical
Review Body of the University of Edinburgh and conducted in
accordance with the UK Animals (Scientific Procedures) Act 1986.
Ovariectomy or sham ovariectomy was performed in 3-month-old adult
female mice as previously described (Idris, 2012). The experiment was
terminated on day 14, and bone mineral density was measured at
the tibial metaphysis by microcomputed tomography (microCT).
17b-Estradiol (E2, 40 lg kg1 day1) or placebo treatments were
administered by slow-release pellets (Innovative Research of America,
Sarasota, Florida, USA) implanted subcutaneously as previously described
(Armour et al., 2001).
Microcomputed tomography
Trabecular and cortical bone microCT analysis was performed as
previously describe in (Campbell & Sophocleous, 2014), using a Skyscan
1172 instrument (Brucker, Belgium) set at 60 kV and 150 lA and at a
resolution of 5 lm. Images were then reconstructed by the Skyscan
NRecon program and analysed using Skyscan CTAn software. The whole
embryos or adult (3-month-old) and aging (12-month-old) mice were
analysed as previously described (Campbell & Sophocleous, 2014).
Trabecular bone was analysed at the left proximal tibial (200 slices
directly distal of the growth plate) and distal femoral metaphysis (200
slices directly proximal of the growth plate) and at the sixth lumbar
vertebra (L6), the ROI encompassed the secondary spongiosa of the
vertebral body extending 1 mm caudally from the cranial spongiosa.
Analysis of cortical bone focused on a region extending 1.25 mm distally
from the mid-point of the femoral diaphysis and a region extending
0.5 mm distally from the mid-point of the tibia.
Bone histomorphometry
Bone histomorphometry was performed on the proximal tibial metaph-
ysis from wild-type and Cnr1/2/ mice. Intraperitoneal injections of
200 lL of Calcein (20 mg kg1, Sigma-Aldrich, Dorset, UK) were given
on day 6 and day 2 prior to the mice being sacrificed in order to assess
dynamic histomorphometry. The bones were fixed, processed for static
and dynamic histomorphometry according to standard techniques and
sectioned using a Leica microtome (Solms, Germany). Sections were
stained with von Kossa, Paragon, tartrate-resistant acid phosphatase
(TRAcP) and aniline blue as previously described (Erben & Glosmann,
2012). Static and dynamic bone histomorphometry were performed on
trabecular bone focusing on an area between 0.1 and 1.0 mm distal to
the growth plate, using custom-built software-generated in-house
based on the Aphelion Image Analysis tool kit (Adcis, He0rouville-
Saint-Clair, France). Three sections, 20 lm apart, were analysed per
sample; and each section was analysed in up to five microscopic fields of
view.
Table 2 Comparison of skeletal phenotype in Cnr1, Cnr2 and Cnr1/2 double-knockout (Cnr1/2/) compared to wild-type mice
Age Genotype BV/TV Ct.Ar Oc.N/BS Ob.N/BS MAR MS/BS BFR/BS
3 months CNR1/ 34. 7.5 4. 2.3ns 54.0  4.8* 7.3  10.9ns 10.2  6.6ns 18.4  4.5 9.1  10.5ns
CNR2/ 55.5  11.2 1.1  2.1ns 31.4  6.3 4.7  5.6ns 21.3  4.1* 9.7  3.8ns 26.8  5.4
CNR1/2/ 39.9  3.4 2.8  2.8ns 22.0  5.2 20.3  4.6+ 5.1  3.5ns 0.7  1.5$ns 3.4  3.9+ns
12 months CNR1/ 11.3  6.2 4.0  3.0ns 91.9  4.6* 54.8  10.7 55.9  10.5 6.9  6.7ns 60.4  8.1
CNR2/ 7.6  7.5ns 4.7  2.3ns 0.0  8.6ns 34.4  5.6 28.3  6.1 21.5  5.4 46.3  6.4
CNR1/2/ 53.3  12.5* 6.4  4.6ns 18.4  6.3ns 33.7  6.2 6.8  5.9*ns 30.4  5.5 25.6  7.3
Values are % change from wild-type. BV/TV; trabecular bone volume; Ct.Ar; cortical area; Oc.N/BS, osteoclast number/bone surface; Ob.N/BS, osteoblast number/bone
surface; MAR, mineral apposition rate; MS/BS, mineralizing surface/ bone surface; BFR/BS: bone formation rate/bone surface; ns, not significant from respective wild-type
control. Values are percentage difference from wild-type and were obtained from six to eight animals (mean  SEM). *P < 0.05 from all genotype groups, +P < 0.05 from
Cnr2/, $P < 0.05 from Cnr1/.
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Biomechanical Testing
Biomechanical testing was performed on tibiae and femorae that had
been kept in sterile PBS and was carried out as previously described
(Sophocleous et al., 2014a). Briefly, long bones were placed in a Zwick/
Roell materials testing machine (Zwick Testing Machines, Leominster,
UK) and subjected to three-point bending at the diaphysis using a 50-N
Zwick/Roell load cell. The span was fixed at 7 mm, and the moving cross
head was lowered at 0.4 mm min1. All samples were tested to
fracture. Failure and fracture points, energy spent to reach these points
and maximum stiffness and yield points were identified from the load–
extension curve. Yield was calculated as the point at which a regression
line that represents a 5% loss in stiffness crosses the load–displacement
curve as described in (Jepsen et al., 2015). A sigmoidal curve fitted to the
rising portion of the load–extension curve was prepared using GraphPad
Prism 4 for Windows (GraphPad Software, San Diego, CA, USA).
Cultures and reagents
All chemicals and reagents were purchased from Sigma-Aldrich unless
otherwise stated. The Cnr1-selective inverse agonist AM251 was pur-
chased from Tocris Biosciences (Bristol, UK). The mouse preadipocyte 3T3-
L1 cells were purchased from Sigma-Aldrich (Ntambi & Young-Cheul,
2000) and were cultured in standard (D-MEM supplemented with 10%
foetal calf serum (FCS), 5% L-glutamine, 100 U mL1 penicillin and
100 lg mL1 streptomycin) or adipogenic medium (standard medium
supplemented with insulin (1 lg mL1), indomethacin (0.1 lM) and
dexamethasone (250 nM). Mouse osteoclasts were generated from bone
marrow (BM) cells as previously described in Sophocleous et al. (2015).
Primary BM osteoblasts were generated from bone marrow (BM) cells in
standard alpha-MEM, supplemented with 10% FCS, penicillin and
streptomycin, b-glycerol phosphate (10 lM) and L-ascorbic acid
(50 lg mL1) (Idris et al., 2009). Primary calvarial osteoblasts were
isolated from the calvarial bones of two-day-old mice by sequential
collagenase digestion as previously described (Taylor et al., 2014).
Measurement of protein expression
Western blot analysis was used to detect Cnr1 and FABP4 expression in
cultured mouse preadipocyte 3T3-L1 cells as previously described in
Sophocleous et al. (2015). Protein concentration was determined using
BCA assay (Pierce, USA). Total protein (70 lg) was resolved by SDS–
PAGE, transferred onto PVDF membranes (Bio-RAD, Hamburg, Ger-
many) and immunoblotted with antibodies according to manufacturer’s
instructions. Detection of human FABP4 (Cell Signalling Technology,
Danvers, Massachusetts, USA) and mouse Cnr1 (Cayman Chemical,
Hamburg, Germany) was performed using rabbit monoclonal antibodies
(Cell Signalling Technology) followed by appropriate secondary antibody
coupled to horseradish peroxidase and then visualized using chemilumi-
nescence (Amersham, Hamburg, Germany) on a Syngene GeneGnome
imaging system. The intensity of the bands was quantified using
GeneSnap software (Syngene, UK), and level of actin expression was
used for normalization.
Quantification of adipocyte function and viability
Nile Red staining was used to assess adipocyte function by visualizing
lipid droplets in 3T3-L1 cells as described in Greenspan et al. (1985).
AlamarBlue assay was used to assess cell viability as described in
Gloeckner et al. (2001).
Assessment of gene expression
Gene expression was detected using quantitative PCR (qPCR) as
previously described (Aitken et al., 2009). Briefly, cells were lysed using
TRIzol reagent, separated with chloroform and precipitated with
isopropyl alcohol. The pellet was suspended in DEPC-treated water,
and samples were quantified using a Nanodrop ND-8000. Complemen-
tary DNA (cDNA) was generated using Invitrogen SuperScript III Reverse
Transcriptase kit according to manufacturer’s instructions. Quantitative
real-time PCR (qPCR) was performed on the cDNA using mouse targeted
primer/probe combination sets designed according to the Roche
Universal Probe Library (UPL). For verification of amplification, the
product was cleaned using a PCR purification kit (Invitrogen) and then
run and visualized on a 1.5% agarose gel adjacent to a low-molecular-
weight ladder. Full list of primers used for amplification of osteoclast,
osteoblast and adipocyte-specific genes is shown in Table S2. Levels of
gene expression were expressed as copy number per microgram of total
RNA, and 18s was used for cDNA normalization.
Statistical analysis
Statistical analyses were performed using IBM (Armonk, NY, USA) SPSS
Statistics, version 19. Comparison between groups was made by
independent-samples t-test, and the significance level was set at
P = 0.05. Pearson’s correlation coefficients (R) values were calculated
by bivariate correlation with a two-tailed test of significance. Significant
differences between genotypes with regard to % change from their own
wild-type were assessed using one-way analysis of variance (ANOVA)
followed by Tukey HSD post hoc test (for equal variances) or Games–
Howell post hoc test (for unequal variances). The significance level was
set at P = 0.05
Acknowledgments
A. I. Idris and S. H. Ralston are inventors on a patent concerning the use
of cannabinoid receptor ligands as treatments other bone diseases.
Funding info
This research was funded by a programme grant from Arthritis Research
UK (reference 17713).
Author contributions
Antonia Sophocleous involved in experimental work and data analysis;
Silvia Marino involved in experimental work and data analysis; Dilruba
Kabir involved in experimental work; Stuart H. Ralston was principal
investigator and involved in conception, editing and writing; and Aymen
I. Idris involved in conception, experimental, analysis, editing and writing.
Conflict of interest
A. Sophocleous, S. Marino and D. Kabir report that they have no conflict
of interest.
References
Agudo J, Martin M, Roca C, Molas M, Bura AS, Zimmer A, Bosch F, Maldonado R.
(2010) Deficiency of CB2 cannabinoid receptor in mice improves insulin
sensitivity but increases food intake and obesity with age. Diabetologia 53,
2629–2640.
Osteoprotection by Cnr1/2 deficiency, A. Sophocleous et al.1060
ª 2017 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd.
Aitken SJ, Landao-Bassonga E, Ralston SH, Idris AI (2009) Beta2-adrenoreceptor
ligands regulate osteoclast differentiation in vitro by direct and indirect
mechanisms. Arch. Biochem. Biophys. 482, 96–103.
Armour KE, Armour KJ, Gallagher ME, Godecke A, Helfrich MH, Reid DM, Ralston
SH (2001) Defective bone formation and anabolic response to exogenous
estrogen in mice with targeted disruption of endothelial nitric oxide synthase.
Endocrinology 142, 760–766.
Bab I, Zimmer A, Melamed E (2009) Cannabinoids and the skeleton: From
marijuana to reversal of bone loss. Ann. Med., 41, 560–7.
Burton GR, Nagarajan R, Peterson CA, McGehee RE Jr (2004) Microarray analysis of
differentiation-specific gene expression during 3T3-L1 adipogenesis. Gene 329,
167–185.
Campbell GM, Sophocleous A (2014) Quantitative analysis of bone and soft tissue
by micro-computed tomography: applications to ex vivo and in vivo studies.
BoneKEy Rep. 3, 564.
Champigny O, Holloway BR, Ricquier D (1992) Regulation of UCP gene expression
in brown adipocytes differentiated in primary culture. Effects of a new beta-
adrenoceptor agonist. Mol. Cell. Endocrinol. 86, 73–82.
Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa GL (1998) Appetite
suppression and weight loss after the cannabinoid antagonist SR 141716. Life
Sci. 63, PL113–PL117.
Cota D (2007) CB1 receptors: emerging evidence for central and peripheral
mechanisms that regulate energy balance, metabolism, and cardiovascular
health. Diabetes Metab Res Rev. 23, 507–517.
Demuth DG, Molleman A (2006) Cannabinoid signalling. Life Sci. 78, 549–563.
Erben RG, Glosmann M (2012) Histomorphometry in rodents. Methods Mol. Biol.
816, 279–303.
Gloeckner H, Jonuleit T, Lemke HD (2001) Monitoring of cell viability and cell
growth in a hollow-fiber bioreactor by use of the dye Alamar Blue. J. Immunol.
Methods 252, 131–138.
Greenspan P, Mayer EP, Fowler SD (1985) Nile red: a selective fluorescent stain for
intracellular lipid droplets. J. Cell Biol. 100, 965–973.
Idris AI (2012) Ovariectomy/orchidectomy in rodents. Methods Mol. Biol. 816,
545–551.
Idris AI, Ralston SH (2010) Cannabinoids and bone: friend or foe? Calcif. Tissue Int.
87, 285–297.
Idris AI, Ralston SH (2012) Role of cannabinoids in the regulation of bone
remodeling. Front Endocrinol.(Lausanne). 3, 136.
Idris AI, Van‘t Hof RJ, Greig IR, Ridge SA, Baker D, Ross RA, Ralston SH (2005)
Regulation of bone mass, bone loss and osteoclast activity by cannabinoid
receptors. Nat. Med. 11, 774–779.
Idris AI, Sophocleous A, Landao-Bassonga E, van’t HR, Ralston SH (2008)
Regulation of bone mass, osteoclast function, and ovariectomy-induced
bone loss by the type 2 cannabinoid receptor. Endocrinology 149,
5619–5626.
Idris AI, Sophocleous A, Landao-Bassonga E, Canals M, Milligan G, Baker D, van’t
HR, Ralston SH (2009) Cannabinoid receptor type 1 protects against age-related
osteoporosis by regulating osteoblast and adipocyte differentiation in marrow
stromal cells. Cell Metab. 10, 139–147.
Jepsen KJ, Silva MJ, Vashishth D, Guo XE, van der Meulen MC (2015) Establishing
biomechanical mechanisms in mouse models: practical guidelines for systemat-
ically evaluating phenotypic changes in the diaphyses of long bones. J. Bone
Miner. Res. 30, 951–966.
Kirkham TC, Williams CM (2001) Endogenous cannabinoids and appetite. Nutr.
Res. Rev. 14, 65–86.
Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, Bohme GA, Imperato
A, Pedrazzini T, Roques BP, Vassart G, Fratta W, Parmentier M (1999)
Unresponsiveness to cannabinoids and reduced addictive effects of opiates in
CB1 receptor knockout mice. Science 283, 401–404.
Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, Hermann H,
Tang J, Hofmann C, Zieglgansberger W, Di Marzo V, Lutz B (2002) The
endogenous cannabinoid system controls extinction of aversive memories.
Nature 418, 530–534.
Matias I, Pochard P, Orlando P, Salzet M, Pestel J, Di MV (2002) Presence and
regulation of the endocannabinoid system in human dendritic cells. Eur. J.
Biochem. 269, 3771–3778.
Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990) Structure of a
cannabinoid receptor and functional expression of the cloned cDNA. Nature
346, 561–564.
Mechoulam R (2005) Plant cannabinoids: a neglected pharmacological treasure
trove. Br. J. Pharmacol. 146, 913–915.
Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a
peripheral receptor for cannabinoids. Nature 365, 61–65.
Ntambi JM, Young-Cheul K (2000) Adipocyte differentiation and gene expression.
J. Nutr. 130, 3122S–3126S.
Ofek O, Karsak M, Leclerc N, Fogel M, Frenkel B, Wright K, Tam J, Attar-Namdar
M, Kram V, Shohami E, Mechoulam R, Zimmer A, Bab I (2006) Peripheral
cannabinoid receptor, CB2, regulates bone mass. Proc. Natl Acad. Sci. USA 103,
696–701.
Ofek O, Attar-Namdar M, Kram V, Dvir-Ginzberg M, Mechoulam R, Zimmer A,
Frenkel B, Shohami E, Bab I (2011) CB2 cannabinoid receptor targets mitogenic
Gi protein-cyclin D1 axis in osteoblasts. J. Bone Miner. Res. 26, 308–316.
Pacifici R (1996) Estrogen, cytokines, and pathogenesis of postmenopausal
osteoporosis. J. Bone Miner. Res. 11, 1043–1051.
Pertwee RG, Ross RA (2002) Cannabinoid receptors and their ligands. Prostaglan-
dins Leukot. Essent. Fatty Acids 66, 101–121.
Raisz LG (1996) Estrogen and bone: new pieces to the puzzle. Nat. Med. 2, 1077–
1078.
Richelson LS, Wahner HW, Melton LJ 3rd, Riggs BL (1984) Relative contributions of
aging and estrogen deficiency to postmenopausal bone loss. N. Engl. J. Med.
311, 1273–1275.
Rossi F, Siniscalco D, Luongo L, De Petrocellis L, Bellini G, Petrosino S, Torella M,
Santoro C, Nobili B, Perrotta S, Di MV, Maione S (2009) The endovanilloid/
endocannabinoid system in human osteoclasts: possible involvement in bone
formation and resorption. Bone 44, 476–484.
Sophocleous A, Landao-Bassonga E, Van’t Hof RJ, Idris AI, Ralston SH (2011) The
type 2 cannabinoid receptor regulates bone mass and ovariectomy-induced
bone loss by affecting osteoblast differentiation and bone formation.
Endocrinology 152, 2141–2149.
Sophocleous A, Idris AI, Ralston SH (2014a) Genetic background modifies the
effects of type 2 cannabinoid receptor deficiency on bone mass and bone
turnover. Calcif. Tissue Int. 94, 259–268.
Sophocleous A, Sims AH, Idris AI, Ralston SH (2014b) Modulation of strain-specific
differences in gene expression by cannabinoid type 2 receptor deficiency. Calcif.
Tissue Int. 94, 423–432.
Sophocleous A, Marino S, Logan JG, Mollat P, Ralston SH, Idris AI (2015) Bone cell-
autonomous contribution of type 2 cannabinoid receptor to breast cancer
induced osteolysis. J. Biol. Chem. 290, 22049–22060.
Sophocleous A, Robertson R, Ferreira NB, McKenzie J, Fraser WD, Ralston SH
(2017) Heavy cannabis use is associated with low bone mineral density and an
increased risk of fractures. Am. J. Med. 130, 214–221.
Tam J, Ofek O, Fride E, Ledent C, Gabet Y, Muller R, Zimmer A, Mackie K,
Mechoulam R, Shohami E, Bab I (2006) Involvement of neuronal cannabinoid
receptor, CB1, in regulation of bone mass and bone remodeling. Mol.
Pharmacol. 70, 786–792.
Tam J, Trembovler V, Di MV, Petrosino S, Leo G, Alexandrovich A, Regev E, Casap
N, Shteyer A, Ledent C, Karsak M, Zimmer A, Mechoulam R, Yirmiya R, Shohami
E, Bab I (2008) The cannabinoid CB1 receptor regulates bone formation by
modulating adrenergic signaling. FASEB J. 22, 285–294.
Taylor SEB, Shah M, Orriss IR (2014) Generation of rodent and human osteoblasts.
BoneKEy Rep. 3, 585.
Whyte LS, Ford L, Ridge SA, Cameron GA, Rogers MJ, Ross RA (2011)
Cannabinoids and bone: Endocannabinoids modulate human osteoclast func-
tion in vitro. Br. J. Pharmacol. 165, 2584–97.
Supporting Information
Additional Supporting Information may be found online in the supporting
information tab for this article.
Fig. S1 Method of generation of Cnr1/2 double knockout mice.
Fig. S2 Increased trabecular bone mass in adult male mice with combined
deficiency in Cnr1 and Cnr2 receptors.
Fig. S3 Increased trabecular bone mass in adult female mice with combined
deficiency in Cnr1 and Cnr2 receptors.
Fig. S4 Increased bone mass in aged female mice with combined deficiency
in Cnr1 and Cnr2 receptors.
Table S1 Body weight in Cnr1/2 double knockout and wild type control mice
Table S2 Primers used for amplification of mouse and human osteoclast,
osteoblast and adipocyte specific genes.
Osteoprotection by Cnr1/2 deficiency, A. Sophocleous et al. 1061
ª 2017 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd.
